Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib plus ruxolitinib versus placebo plus ruxolitinib in myelofibrosis with suboptimal response to ruxolitinib
jRCT2031200424Suspended
- Sponsor
- Incyte
- Start
- Jun 2021
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in myelofibrosis (MF) comparing Parsaclisib + ruxolitinib with Placebo + ruxolitinib (2 arms). Primary endpoint: Proportion of participants achieving targeted reduction in spleen volume. Started Jun 2021; status: suspended.
02
Drugs
parsaclisibruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on jRCT2031200424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200424.